Report Overview
Minimal residual disease (MRD) is a term used to describe the small number of cancer cells in the body after cancer treatment. An MRD positive test result means that disease was still detected after treatment. An MRD negative result means that no disease was detected after treatment.
The global Cancer Minimal Residual Disease Testing market size was estimated at USD 956.60 million in 2023 and is projected to reach USD 1758.67 million by 2032, exhibiting a CAGR of 7.00% during the forecast period.
North America Cancer Minimal Residual Disease Testing market size was estimated at USD 280.07 million in 2023, at a CAGR of 6.00% during the forecast period of 2025 through 2032.
This report provides a deep insight into the global Cancer Minimal Residual Disease Testing market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Cancer Minimal Residual Disease Testing Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Cancer Minimal Residual Disease Testing market in any manner.
Global Cancer Minimal Residual Disease Testing Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Adaptive Biotechnologies Corporation
ArcherDX
Inc. (Invitae Corporation)
Asuragen
Arup Laboratories
Bio-Rad Laboratories
Cergentis B.V.
F. Hoffmann- La Roche Ltd
Guardant Health
ICON plc
Invivoscribe
Laboratory Corporation of America Holdings
Mission Bio
Natera
Inc.
NeoGenomics Laboratories
Opko Health
Quest Diagnostics Incorporated
Sysmex Corporation
Genetron Health
Market Segmentation (by Type)
Flow Cytometry
Polymerase Chain Reaction (PCR)
Next-Generation Sequencing (NGS)
Other
Market Segmentation (by Application)
Hematological Malignancies
Leukemia
Lymphoma
Solid Tumors
Other
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Cancer Minimal Residual Disease Testing Market
Overview of the regional outlook of the Cancer Minimal Residual Disease Testing Market:
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter
TABLE OF CONTENTS
Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Cancer Minimal Residual Disease Testing
1.2 Key Market Segments
1.2.1 Cancer Minimal Residual Disease Testing Segment by Type
1.2.2 Cancer Minimal Residual Disease Testing Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Cancer Minimal Residual Disease Testing Market Overview
2.1 Global Market Overview
2.1.1 Global Cancer Minimal Residual Disease Testing Market Size (M USD) Estimates and Forecasts (2019-2032)
2.1.2 Global Cancer Minimal Residual Disease Testing Sales Estimates and Forecasts (2019-2032)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Cancer Minimal Residual Disease Testing Market Competitive Landscape
3.1 Global Cancer Minimal Residual Disease Testing Sales by Manufacturers (2019-2025)
3.2 Global Cancer Minimal Residual Disease Testing Revenue Market Share by Manufacturers (2019-2025)
3.3 Cancer Minimal Residual Disease Testing Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Cancer Minimal Residual Disease Testing Average Price by Manufacturers (2019-2025)
3.5 Manufacturers Cancer Minimal Residual Disease Testing Sales Sites, Area Served, Product Type
3.6 Cancer Minimal Residual Disease Testing Market Competitive Situation and Trends
3.6.1 Cancer Minimal Residual Disease Testing Market Concentration Rate
3.6.2 Global 5 and 10 Largest Cancer Minimal Residual Disease Testing Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Cancer Minimal Residual Disease Testing Industry Chain Analysis
4.1 Cancer Minimal Residual Disease Testing Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Cancer Minimal Residual Disease Testing Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Cancer Minimal Residual Disease Testing Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Cancer Minimal Residual Disease Testing Sales Market Share by Type (2019-2025)
6.3 Global Cancer Minimal Residual Disease Testing Market Size Market Share by Type (2019-2025)
6.4 Global Cancer Minimal Residual Disease Testing Price by Type (2019-2025)
7 Cancer Minimal Residual Disease Testing Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Cancer Minimal Residual Disease Testing Market Sales by Application (2019-2025)
7.3 Global Cancer Minimal Residual Disease Testing Market Size (M USD) by Application (2019-2025)
7.4 Global Cancer Minimal Residual Disease Testing Sales Growth Rate by Application (2019-2025)
8 Cancer Minimal Residual Disease Testing Market Consumption by Region
8.1 Global Cancer Minimal Residual Disease Testing Sales by Region
8.1.1 Global Cancer Minimal Residual Disease Testing Sales by Region
8.1.2 Global Cancer Minimal Residual Disease Testing Sales Market Share by Region
8.2 North America
8.2.1 North America Cancer Minimal Residual Disease Testing Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Cancer Minimal Residual Disease Testing Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Cancer Minimal Residual Disease Testing Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Cancer Minimal Residual Disease Testing Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Cancer Minimal Residual Disease Testing Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Cancer Minimal Residual Disease Testing Market Production by Region
9.1 Global Production of Cancer Minimal Residual Disease Testing by Region (2019-2025)
9.2 Global Cancer Minimal Residual Disease Testing Revenue Market Share by Region (2019-2025)
9.3 Global Cancer Minimal Residual Disease Testing Production, Revenue, Price and Gross Margin (2019-2025)
9.4 North America Cancer Minimal Residual Disease Testing Production
9.4.1 North America Cancer Minimal Residual Disease Testing Production Growth Rate (2019-2025)
9.4.2 North America Cancer Minimal Residual Disease Testing Production, Revenue, Price and Gross Margin (2019-2025)
9.5 Europe Cancer Minimal Residual Disease Testing Production
9.5.1 Europe Cancer Minimal Residual Disease Testing Production Growth Rate (2019-2025)
9.5.2 Europe Cancer Minimal Residual Disease Testing Production, Revenue, Price and Gross Margin (2019-2025)
9.6 Japan Cancer Minimal Residual Disease Testing Production (2019-2025)
9.6.1 Japan Cancer Minimal Residual Disease Testing Production Growth Rate (2019-2025)
9.6.2 Japan Cancer Minimal Residual Disease Testing Production, Revenue, Price and Gross Margin (2019-2025)
9.7 China Cancer Minimal Residual Disease Testing Production (2019-2025)
9.7.1 China Cancer Minimal Residual Disease Testing Production Growth Rate (2019-2025)
9.7.2 China Cancer Minimal Residual Disease Testing Production, Revenue, Price and Gross Margin (2019-2025)
10 Key Companies Profile
10.1 Adaptive Biotechnologies Corporation
10.1.1 Adaptive Biotechnologies Corporation Cancer Minimal Residual Disease Testing Basic Information
10.1.2 Adaptive Biotechnologies Corporation Cancer Minimal Residual Disease Testing Product Overview
10.1.3 Adaptive Biotechnologies Corporation Cancer Minimal Residual Disease Testing Product Market Performance
10.1.4 Adaptive Biotechnologies Corporation Business Overview
10.1.5 Adaptive Biotechnologies Corporation Cancer Minimal Residual Disease Testing SWOT Analysis
10.1.6 Adaptive Biotechnologies Corporation Recent Developments
10.2 ArcherDX
10.2.1 ArcherDX Cancer Minimal Residual Disease Testing Basic Information
10.2.2 ArcherDX Cancer Minimal Residual Disease Testing Product Overview
10.2.3 ArcherDX Cancer Minimal Residual Disease Testing Product Market Performance
10.2.4 ArcherDX Business Overview
10.2.5 ArcherDX Cancer Minimal Residual Disease Testing SWOT Analysis
10.2.6 ArcherDX Recent Developments
10.3 Inc. (Invitae Corporation)
10.3.1 Inc. (Invitae Corporation) Cancer Minimal Residual Disease Testing Basic Information
10.3.2 Inc. (Invitae Corporation) Cancer Minimal Residual Disease Testing Product Overview
10.3.3 Inc. (Invitae Corporation) Cancer Minimal Residual Disease Testing Product Market Performance
10.3.4 Inc. (Invitae Corporation) Cancer Minimal Residual Disease Testing SWOT Analysis
10.3.5 Inc. (Invitae Corporation) Business Overview
10.3.6 Inc. (Invitae Corporation) Recent Developments
10.4 Asuragen
10.4.1 Asuragen Cancer Minimal Residual Disease Testing Basic Information
10.4.2 Asuragen Cancer Minimal Residual Disease Testing Product Overview
10.4.3 Asuragen Cancer Minimal Residual Disease Testing Product Market Performance
10.4.4 Asuragen Business Overview
10.4.5 Asuragen Recent Developments
10.5 Arup Laboratories
10.5.1 Arup Laboratories Cancer Minimal Residual Disease Testing Basic Information
10.5.2 Arup Laboratories Cancer Minimal Residual Disease Testing Product Overview
10.5.3 Arup Laboratories Cancer Minimal Residual Disease Testing Product Market Performance
10.5.4 Arup Laboratories Business Overview
10.5.5 Arup Laboratories Recent Developments
10.6 Bio-Rad Laboratories
10.6.1 Bio-Rad Laboratories Cancer Minimal Residual Disease Testing Basic Information
10.6.2 Bio-Rad Laboratories Cancer Minimal Residual Disease Testing Product Overview
10.6.3 Bio-Rad Laboratories Cancer Minimal Residual Disease Testing Product Market Performance
10.6.4 Bio-Rad Laboratories Business Overview
10.6.5 Bio-Rad Laboratories Recent Developments
10.7 Cergentis B.V.
10.7.1 Cergentis B.V. Cancer Minimal Residual Disease Testing Basic Information
10.7.2 Cergentis B.V. Cancer Minimal Residual Disease Testing Product Overview
10.7.3 Cergentis B.V. Cancer Minimal Residual Disease Testing Product Market Performance
10.7.4 Cergentis B.V. Business Overview
10.7.5 Cergentis B.V. Recent Developments
10.8 F. Hoffmann- La Roche Ltd
10.8.1 F. Hoffmann- La Roche Ltd Cancer Minimal Residual Disease Testing Basic Information
10.8.2 F. Hoffmann- La Roche Ltd Cancer Minimal Residual Disease Testing Product Overview
10.8.3 F. Hoffmann- La Roche Ltd Cancer Minimal Residual Disease Testing Product Market Performance
10.8.4 F. Hoffmann- La Roche Ltd Business Overview
10.8.5 F. Hoffmann- La Roche Ltd Recent Developments
10.9 Guardant Health
10.9.1 Guardant Health Cancer Minimal Residual Disease Testing Basic Information
10.9.2 Guardant Health Cancer Minimal Residual Disease Testing Product Overview
10.9.3 Guardant Health Cancer Minimal Residual Disease Testing Product Market Performance
10.9.4 Guardant Health Business Overview
10.9.5 Guardant Health Recent Developments
10.10 ICON plc
10.10.1 ICON plc Cancer Minimal Residual Disease Testing Basic Information
10.10.2 ICON plc Cancer Minimal Residual Disease Testing Product Overview
10.10.3 ICON plc Cancer Minimal Residual Disease Testing Product Market Performance
10.10.4 ICON plc Business Overview
10.10.5 ICON plc Recent Developments
10.11 Invivoscribe
10.11.1 Invivoscribe Cancer Minimal Residual Disease Testing Basic Information
10.11.2 Invivoscribe Cancer Minimal Residual Disease Testing Product Overview
10.11.3 Invivoscribe Cancer Minimal Residual Disease Testing Product Market Performance
10.11.4 Invivoscribe Business Overview
10.11.5 Invivoscribe Recent Developments
10.12 Laboratory Corporation of America Holdings
10.12.1 Laboratory Corporation of America Holdings Cancer Minimal Residual Disease Testing Basic Information
10.12.2 Laboratory Corporation of America Holdings Cancer Minimal Residual Disease Testing Product Overview
10.12.3 Laboratory Corporation of America Holdings Cancer Minimal Residual Disease Testing Product Market Performance
10.12.4 Laboratory Corporation of America Holdings Business Overview
10.12.5 Laboratory Corporation of America Holdings Recent Developments
10.13 Mission Bio
10.13.1 Mission Bio Cancer Minimal Residual Disease Testing Basic Information
10.13.2 Mission Bio Cancer Minimal Residual Disease Testing Product Overview
10.13.3 Mission Bio Cancer Minimal Residual Disease Testing Product Market Performance
10.13.4 Mission Bio Business Overview
10.13.5 Mission Bio Recent Developments
10.14 Natera
10.14.1 Natera Cancer Minimal Residual Disease Testing Basic Information
10.14.2 Natera Cancer Minimal Residual Disease Testing Product Overview
10.14.3 Natera Cancer Minimal Residual Disease Testing Product Market Performance
10.14.4 Natera Business Overview
10.14.5 Natera Recent Developments
10.15 Inc.
10.15.1 Inc. Cancer Minimal Residual Disease Testing Basic Information
10.15.2 Inc. Cancer Minimal Residual Disease Testing Product Overview
10.15.3 Inc. Cancer Minimal Residual Disease Testing Product Market Performance
10.15.4 Inc. Business Overview
10.15.5 Inc. Recent Developments
10.16 NeoGenomics Laboratories
10.16.1 NeoGenomics Laboratories Cancer Minimal Residual Disease Testing Basic Information
10.16.2 NeoGenomics Laboratories Cancer Minimal Residual Disease Testing Product Overview
10.16.3 NeoGenomics Laboratories Cancer Minimal Residual Disease Testing Product Market Performance
10.16.4 NeoGenomics Laboratories Business Overview
10.16.5 NeoGenomics Laboratories Recent Developments
10.17 Opko Health
10.17.1 Opko Health Cancer Minimal Residual Disease Testing Basic Information
10.17.2 Opko Health Cancer Minimal Residual Disease Testing Product Overview
10.17.3 Opko Health Cancer Minimal Residual Disease Testing Product Market Performance
10.17.4 Opko Health Business Overview
10.17.5 Opko Health Recent Developments
10.18 Quest Diagnostics Incorporated
10.18.1 Quest Diagnostics Incorporated Cancer Minimal Residual Disease Testing Basic Information
10.18.2 Quest Diagnostics Incorporated Cancer Minimal Residual Disease Testing Product Overview
10.18.3 Quest Diagnostics Incorporated Cancer Minimal Residual Disease Testing Product Market Performance
10.18.4 Quest Diagnostics Incorporated Business Overview
10.18.5 Quest Diagnostics Incorporated Recent Developments
10.19 Sysmex Corporation
10.19.1 Sysmex Corporation Cancer Minimal Residual Disease Testing Basic Information
10.19.2 Sysmex Corporation Cancer Minimal Residual Disease Testing Product Overview
10.19.3 Sysmex Corporation Cancer Minimal Residual Disease Testing Product Market Performance
10.19.4 Sysmex Corporation Business Overview
10.19.5 Sysmex Corporation Recent Developments
10.20 Genetron Health
10.20.1 Genetron Health Cancer Minimal Residual Disease Testing Basic Information
10.20.2 Genetron Health Cancer Minimal Residual Disease Testing Product Overview
10.20.3 Genetron Health Cancer Minimal Residual Disease Testing Product Market Performance
10.20.4 Genetron Health Business Overview
10.20.5 Genetron Health Recent Developments
11 Cancer Minimal Residual Disease Testing Market Forecast by Region
11.1 Global Cancer Minimal Residual Disease Testing Market Size Forecast
11.2 Global Cancer Minimal Residual Disease Testing Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Cancer Minimal Residual Disease Testing Market Size Forecast by Country
11.2.3 Asia Pacific Cancer Minimal Residual Disease Testing Market Size Forecast by Region
11.2.4 South America Cancer Minimal Residual Disease Testing Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Consumption of Cancer Minimal Residual Disease Testing by Country
12 Forecast Market by Type and by Application (2025-2032)
12.1 Global Cancer Minimal Residual Disease Testing Market Forecast by Type (2025-2032)
12.1.1 Global Forecasted Sales of Cancer Minimal Residual Disease Testing by Type (2025-2032)
12.1.2 Global Cancer Minimal Residual Disease Testing Market Size Forecast by Type (2025-2032)
12.1.3 Global Forecasted Price of Cancer Minimal Residual Disease Testing by Type (2025-2032)
12.2 Global Cancer Minimal Residual Disease Testing Market Forecast by Application (2025-2032)
12.2.1 Global Cancer Minimal Residual Disease Testing Sales (K Units) Forecast by Application
12.2.2 Global Cancer Minimal Residual Disease Testing Market Size (M USD) Forecast by Application (2025-2032)
13 Conclusion and Key Findings
LIST OF TABLES & FIGURES
List of Tables
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Cancer Minimal Residual Disease Testing Market Size Comparison by Region (M USD)
Table 5. Global Cancer Minimal Residual Disease Testing Sales (K Units) by Manufacturers (2019-2025)
Table 6. Global Cancer Minimal Residual Disease Testing Sales Market Share by Manufacturers (2019-2025)
Table 7. Global Cancer Minimal Residual Disease Testing Revenue (M USD) by Manufacturers (2019-2025)
Table 8. Global Cancer Minimal Residual Disease Testing Revenue Share by Manufacturers (2019-2025)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Minimal Residual Disease Testing as of 2022)
Table 10. Global Market Cancer Minimal Residual Disease Testing Average Price (USD/Unit) of Key Manufacturers (2019-2025)
Table 11. Manufacturers Cancer Minimal Residual Disease Testing Sales Sites and Area Served
Table 12. Manufacturers Cancer Minimal Residual Disease Testing Product Type
Table 13. Global Cancer Minimal Residual Disease Testing Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Cancer Minimal Residual Disease Testing
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Cancer Minimal Residual Disease Testing Market Challenges
Table 22. Global Cancer Minimal Residual Disease Testing Sales by Type (K Units)
Table 23. Global Cancer Minimal Residual Disease Testing Market Size by Type (M USD)
Table 24. Global Cancer Minimal Residual Disease Testing Sales (K Units) by Type (2019-2025)
Table 25. Global Cancer Minimal Residual Disease Testing Sales Market Share by Type (2019-2025)
Table 26. Global Cancer Minimal Residual Disease Testing Market Size (M USD) by Type (2019-2025)
Table 27. Global Cancer Minimal Residual Disease Testing Market Size Share by Type (2019-2025)
Table 28. Global Cancer Minimal Residual Disease Testing Price (USD/Unit) by Type (2019-2025)
Table 29. Global Cancer Minimal Residual Disease Testing Sales (K Units) by Application
Table 30. Global Cancer Minimal Residual Disease Testing Market Size by Application
Table 31. Global Cancer Minimal Residual Disease Testing Sales by Application (2019-2025) & (K Units)
Table 32. Global Cancer Minimal Residual Disease Testing Sales Market Share by Application (2019-2025)
Table 33. Global Cancer Minimal Residual Disease Testing Sales by Application (2019-2025) & (M USD)
Table 34. Global Cancer Minimal Residual Disease Testing Market Share by Application (2019-2025)
Table 35. Global Cancer Minimal Residual Disease Testing Sales Growth Rate by Application (2019-2025)
Table 36. Global Cancer Minimal Residual Disease Testing Sales by Region (2019-2025) & (K Units)
Table 37. Global Cancer Minimal Residual Disease Testing Sales Market Share by Region (2019-2025)
Table 38. North America Cancer Minimal Residual Disease Testing Sales by Country (2019-2025) & (K Units)
Table 39. Europe Cancer Minimal Residual Disease Testing Sales by Country (2019-2025) & (K Units)
Table 40. Asia Pacific Cancer Minimal Residual Disease Testing Sales by Region (2019-2025) & (K Units)
Table 41. South America Cancer Minimal Residual Disease Testing Sales by Country (2019-2025) & (K Units)
Table 42. Middle East and Africa Cancer Minimal Residual Disease Testing Sales by Region (2019-2025) & (K Units)
Table 43. Global Cancer Minimal Residual Disease Testing Production (K Units) by Region (2019-2025)
Table 44. Global Cancer Minimal Residual Disease Testing Revenue (US$ Million) by Region (2019-2025)
Table 45. Global Cancer Minimal Residual Disease Testing Revenue Market Share by Region (2019-2025)
Table 46. Global Cancer Minimal Residual Disease Testing Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2025)
Table 47. North America Cancer Minimal Residual Disease Testing Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2025)
Table 48. Europe Cancer Minimal Residual Disease Testing Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2025)
Table 49. Japan Cancer Minimal Residual Disease Testing Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2025)
Table 50. China Cancer Minimal Residual Disease Testing Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2025)
Table 51. Adaptive Biotechnologies Corporation Cancer Minimal Residual Disease Testing Basic Information
Table 52. Adaptive Biotechnologies Corporation Cancer Minimal Residual Disease Testing Product Overview
Table 53. Adaptive Biotechnologies Corporation Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 54. Adaptive Biotechnologies Corporation Business Overview
Table 55. Adaptive Biotechnologies Corporation Cancer Minimal Residual Disease Testing SWOT Analysis
Table 56. Adaptive Biotechnologies Corporation Recent Developments
Table 57. ArcherDX Cancer Minimal Residual Disease Testing Basic Information
Table 58. ArcherDX Cancer Minimal Residual Disease Testing Product Overview
Table 59. ArcherDX Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 60. ArcherDX Business Overview
Table 61. ArcherDX Cancer Minimal Residual Disease Testing SWOT Analysis
Table 62. ArcherDX Recent Developments
Table 63. Inc. (Invitae Corporation) Cancer Minimal Residual Disease Testing Basic Information
Table 64. Inc. (Invitae Corporation) Cancer Minimal Residual Disease Testing Product Overview
Table 65. Inc. (Invitae Corporation) Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 66. Inc. (Invitae Corporation) Cancer Minimal Residual Disease Testing SWOT Analysis
Table 67. Inc. (Invitae Corporation) Business Overview
Table 68. Inc. (Invitae Corporation) Recent Developments
Table 69. Asuragen Cancer Minimal Residual Disease Testing Basic Information
Table 70. Asuragen Cancer Minimal Residual Disease Testing Product Overview
Table 71. Asuragen Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 72. Asuragen Business Overview
Table 73. Asuragen Recent Developments
Table 74. Arup Laboratories Cancer Minimal Residual Disease Testing Basic Information
Table 75. Arup Laboratories Cancer Minimal Residual Disease Testing Product Overview
Table 76. Arup Laboratories Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 77. Arup Laboratories Business Overview
Table 78. Arup Laboratories Recent Developments
Table 79. Bio-Rad Laboratories Cancer Minimal Residual Disease Testing Basic Information
Table 80. Bio-Rad Laboratories Cancer Minimal Residual Disease Testing Product Overview
Table 81. Bio-Rad Laboratories Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 82. Bio-Rad Laboratories Business Overview
Table 83. Bio-Rad Laboratories Recent Developments
Table 84. Cergentis B.V. Cancer Minimal Residual Disease Testing Basic Information
Table 85. Cergentis B.V. Cancer Minimal Residual Disease Testing Product Overview
Table 86. Cergentis B.V. Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 87. Cergentis B.V. Business Overview
Table 88. Cergentis B.V. Recent Developments
Table 89. F. Hoffmann- La Roche Ltd Cancer Minimal Residual Disease Testing Basic Information
Table 90. F. Hoffmann- La Roche Ltd Cancer Minimal Residual Disease Testing Product Overview
Table 91. F. Hoffmann- La Roche Ltd Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 92. F. Hoffmann- La Roche Ltd Business Overview
Table 93. F. Hoffmann- La Roche Ltd Recent Developments
Table 94. Guardant Health Cancer Minimal Residual Disease Testing Basic Information
Table 95. Guardant Health Cancer Minimal Residual Disease Testing Product Overview
Table 96. Guardant Health Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 97. Guardant Health Business Overview
Table 98. Guardant Health Recent Developments
Table 99. ICON plc Cancer Minimal Residual Disease Testing Basic Information
Table 100. ICON plc Cancer Minimal Residual Disease Testing Product Overview
Table 101. ICON plc Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 102. ICON plc Business Overview
Table 103. ICON plc Recent Developments
Table 104. Invivoscribe Cancer Minimal Residual Disease Testing Basic Information
Table 105. Invivoscribe Cancer Minimal Residual Disease Testing Product Overview
Table 106. Invivoscribe Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 107. Invivoscribe Business Overview
Table 108. Invivoscribe Recent Developments
Table 109. Laboratory Corporation of America Holdings Cancer Minimal Residual Disease Testing Basic Information
Table 110. Laboratory Corporation of America Holdings Cancer Minimal Residual Disease Testing Product Overview
Table 111. Laboratory Corporation of America Holdings Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 112. Laboratory Corporation of America Holdings Business Overview
Table 113. Laboratory Corporation of America Holdings Recent Developments
Table 114. Mission Bio Cancer Minimal Residual Disease Testing Basic Information
Table 115. Mission Bio Cancer Minimal Residual Disease Testing Product Overview
Table 116. Mission Bio Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 117. Mission Bio Business Overview
Table 118. Mission Bio Recent Developments
Table 119. Natera Cancer Minimal Residual Disease Testing Basic Information
Table 120. Natera Cancer Minimal Residual Disease Testing Product Overview
Table 121. Natera Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 122. Natera Business Overview
Table 123. Natera Recent Developments
Table 124. Inc. Cancer Minimal Residual Disease Testing Basic Information
Table 125. Inc. Cancer Minimal Residual Disease Testing Product Overview
Table 126. Inc. Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 127. Inc. Business Overview
Table 128. Inc. Recent Developments
Table 129. NeoGenomics Laboratories Cancer Minimal Residual Disease Testing Basic Information
Table 130. NeoGenomics Laboratories Cancer Minimal Residual Disease Testing Product Overview
Table 131. NeoGenomics Laboratories Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 132. NeoGenomics Laboratories Business Overview
Table 133. NeoGenomics Laboratories Recent Developments
Table 134. Opko Health Cancer Minimal Residual Disease Testing Basic Information
Table 135. Opko Health Cancer Minimal Residual Disease Testing Product Overview
Table 136. Opko Health Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 137. Opko Health Business Overview
Table 138. Opko Health Recent Developments
Table 139. Quest Diagnostics Incorporated Cancer Minimal Residual Disease Testing Basic Information
Table 140. Quest Diagnostics Incorporated Cancer Minimal Residual Disease Testing Product Overview
Table 141. Quest Diagnostics Incorporated Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 142. Quest Diagnostics Incorporated Business Overview
Table 143. Quest Diagnostics Incorporated Recent Developments
Table 144. Sysmex Corporation Cancer Minimal Residual Disease Testing Basic Information
Table 145. Sysmex Corporation Cancer Minimal Residual Disease Testing Product Overview
Table 146. Sysmex Corporation Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 147. Sysmex Corporation Business Overview
Table 148. Sysmex Corporation Recent Developments
Table 149. Genetron Health Cancer Minimal Residual Disease Testing Basic Information
Table 150. Genetron Health Cancer Minimal Residual Disease Testing Product Overview
Table 151. Genetron Health Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 152. Genetron Health Business Overview
Table 153. Genetron Health Recent Developments
Table 154. Global Cancer Minimal Residual Disease Testing Sales Forecast by Region (2025-2032) & (K Units)
Table 155. Global Cancer Minimal Residual Disease Testing Market Size Forecast by Region (2025-2032) & (M USD)
Table 156. North America Cancer Minimal Residual Disease Testing Sales Forecast by Country (2025-2032) & (K Units)
Table 157. North America Cancer Minimal Residual Disease Testing Market Size Forecast by Country (2025-2032) & (M USD)
Table 158. Europe Cancer Minimal Residual Disease Testing Sales Forecast by Country (2025-2032) & (K Units)
Table 159. Europe Cancer Minimal Residual Disease Testing Market Size Forecast by Country (2025-2032) & (M USD)
Table 160. Asia Pacific Cancer Minimal Residual Disease Testing Sales Forecast by Region (2025-2032) & (K Units)
Table 161. Asia Pacific Cancer Minimal Residual Disease Testing Market Size Forecast by Region (2025-2032) & (M USD)
Table 162. South America Cancer Minimal Residual Disease Testing Sales Forecast by Country (2025-2032) & (K Units)
Table 163. South America Cancer Minimal Residual Disease Testing Market Size Forecast by Country (2025-2032) & (M USD)
Table 164. Middle East and Africa Cancer Minimal Residual Disease Testing Consumption Forecast by Country (2025-2032) & (Units)
Table 165. Middle East and Africa Cancer Minimal Residual Disease Testing Market Size Forecast by Country (2025-2032) & (M USD)
Table 166. Global Cancer Minimal Residual Disease Testing Sales Forecast by Type (2025-2032) & (K Units)
Table 167. Global Cancer Minimal Residual Disease Testing Market Size Forecast by Type (2025-2032) & (M USD)
Table 168. Global Cancer Minimal Residual Disease Testing Price Forecast by Type (2025-2032) & (USD/Unit)
Table 169. Global Cancer Minimal Residual Disease Testing Sales (K Units) Forecast by Application (2025-2032)
Table 170. Global Cancer Minimal Residual Disease Testing Market Size Forecast by Application (2025-2032) & (M USD)
List of Figures
Figure 1. Product Picture of Cancer Minimal Residual Disease Testing
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Cancer Minimal Residual Disease Testing Market Size (M USD), 2019-2032
Figure 5. Global Cancer Minimal Residual Disease Testing Market Size (M USD) (2019-2032)
Figure 6. Global Cancer Minimal Residual Disease Testing Sales (K Units) & (2019-2032)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Cancer Minimal Residual Disease Testing Market Size by Country (M USD)
Figure 11. Cancer Minimal Residual Disease Testing Sales Share by Manufacturers in 2023
Figure 12. Global Cancer Minimal Residual Disease Testing Revenue Share by Manufacturers in 2023
Figure 13. Cancer Minimal Residual Disease Testing Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Cancer Minimal Residual Disease Testing Average Price (USD/Unit) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Cancer Minimal Residual Disease Testing Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Cancer Minimal Residual Disease Testing Market Share by Type
Figure 18. Sales Market Share of Cancer Minimal Residual Disease Testing by Type (2019-2025)
Figure 19. Sales Market Share of Cancer Minimal Residual Disease Testing by Type in 2023
Figure 20. Market Size Share of Cancer Minimal Residual Disease Testing by Type (2019-2025)
Figure 21. Market Size Market Share of Cancer Minimal Residual Disease Testing by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Cancer Minimal Residual Disease Testing Market Share by Application
Figure 24. Global Cancer Minimal Residual Disease Testing Sales Market Share by Application (2019-2025)
Figure 25. Global Cancer Minimal Residual Disease Testing Sales Market Share by Application in 2023
Figure 26. Global Cancer Minimal Residual Disease Testing Market Share by Application (2019-2025)
Figure 27. Global Cancer Minimal Residual Disease Testing Market Share by Application in 2023
Figure 28. Global Cancer Minimal Residual Disease Testing Sales Growth Rate by Application (2019-2025)
Figure 29. Global Cancer Minimal Residual Disease Testing Sales Market Share by Region (2019-2025)
Figure 30. North America Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2025) & (K Units)
Figure 31. North America Cancer Minimal Residual Disease Testing Sales Market Share by Country in 2023
Figure 32. U.S. Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2025) & (K Units)
Figure 33. Canada Cancer Minimal Residual Disease Testing Sales (K Units) and Growth Rate (2019-2025)
Figure 34. Mexico Cancer Minimal Residual Disease Testing Sales (Units) and Growth Rate (2019-2025)
Figure 35. Europe Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2025) & (K Units)
Figure 36. Europe Cancer Minimal Residual Disease Testing Sales Market Share by Country in 2023
Figure 37. Germany Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2025) & (K Units)
Figure 38. France Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2025) & (K Units)
Figure 39. U.K. Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2025) & (K Units)
Figure 40. Italy Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2025) & (K Units)
Figure 41. Russia Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2025) & (K Units)
Figure 42. Asia Pacific Cancer Minimal Residual Disease Testing Sales and Growth Rate (K Units)
Figure 43. Asia Pacific Cancer Minimal Residual Disease Testing Sales Market Share by Region in 2023
Figure 44. China Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2025) & (K Units)
Figure 45. Japan Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2025) & (K Units)
Figure 46. South Korea Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2025) & (K Units)
Figure 47. India Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2025) & (K Units)
Figure 48. Southeast Asia Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2025) & (K Units)
Figure 49. South America Cancer Minimal Residual Disease Testing Sales and Growth Rate (K Units)
Figure 50. South America Cancer Minimal Residual Disease Testing Sales Market Share by Country in 2023
Figure 51. Brazil Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2025) & (K Units)
Figure 52. Argentina Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2025) & (K Units)
Figure 53. Columbia Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2025) & (K Units)
Figure 54. Middle East and Africa Cancer Minimal Residual Disease Testing Sales and Growth Rate (K Units)
Figure 55. Middle East and Africa Cancer Minimal Residual Disease Testing Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2025) & (K Units)
Figure 57. UAE Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2025) & (K Units)
Figure 58. Egypt Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2025) & (K Units)
Figure 59. Nigeria Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2025) & (K Units)
Figure 60. South Africa Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2025) & (K Units)
Figure 61. Global Cancer Minimal Residual Disease Testing Production Market Share by Region (2019-2025)
Figure 62. North America Cancer Minimal Residual Disease Testing Production (K Units) Growth Rate (2019-2025)
Figure 63. Europe Cancer Minimal Residual Disease Testing Production (K Units) Growth Rate (2019-2025)
Figure 64. Japan Cancer Minimal Residual Disease Testing Production (K Units) Growth Rate (2019-2025)
Figure 65. China Cancer Minimal Residual Disease Testing Production (K Units) Growth Rate (2019-2025)
Figure 66. Global Cancer Minimal Residual Disease Testing Sales Forecast by Volume (2019-2032) & (K Units)
Figure 67. Global Cancer Minimal Residual Disease Testing Market Size Forecast by Value (2019-2032) & (M USD)
Figure 68. Global Cancer Minimal Residual Disease Testing Sales Market Share Forecast by Type (2025-2032)
Figure 69. Global Cancer Minimal Residual Disease Testing Market Share Forecast by Type (2025-2032)
Figure 70. Global Cancer Minimal Residual Disease Testing Sales Forecast by Application (2025-2032)
Figure 71. Global Cancer Minimal Residual Disease Testing Market Share Forecast by Application (2025-2032)
